Compare DNP & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNP | LIVN |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 1995 | 2015 |
| Metric | DNP | LIVN |
|---|---|---|
| Price | $10.73 | $77.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $72.43 |
| AVG Volume (30 Days) | ★ 681.4K | 664.8K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.79 |
| Revenue Next Year | N/A | $6.63 |
| P/E Ratio | ★ N/A | $197.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.65 | $41.02 |
| 52 Week High | $10.92 | $80.96 |
| Indicator | DNP | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 60.66 |
| Support Level | $10.59 | $61.63 |
| Resistance Level | $10.85 | N/A |
| Average True Range (ATR) | 0.12 | 2.44 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 77.42 | 68.29 |
DNP Select Income Fund Inc is a closed-ended investment management fund. Its investment objectives are current income and long-term growth of income, with capital appreciation as a secondary objective. The Fund seeks to achieve its investment objectives by investing mainly in a diversified portfolio of equity and fixed-income securities of companies in the public utilities industry. Under normal market conditions, more than 65% of the Fund's total assets are invested in securities of public utility companies engaged in the production, transmission, or distribution of electric energy, gas, or telephone services.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.